Cargando…
SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era
Background: Nation-wide SARS-CoV-2 seroprevalence surveys provide valuable insights into the course of the pandemic, including information often not captured by routine surveillance of reported cases. Methods: A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between March an...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871128/ https://www.ncbi.nlm.nih.gov/pubmed/35204386 http://dx.doi.org/10.3390/diagnostics12020295 |
_version_ | 1784656922585071616 |
---|---|
author | Koureas, Michalis Bogogiannidou, Zacharoula Vontas, Alexandros Kyritsi, Maria A. Mouchtouri, Varvara A. Dadouli, Katerina Anagnostopoulos, Lemonia Mina, Paraskevi Matziri, Alexia Ntouska, Maria Tsigaridaki, Maria Gkiata, Vasiliki Tsilidis, Konstantinos K. Ntzani, Evangelia E. Prezerakos, Panagiotis Tsiodras, Sotirios Speletas, Matthaios Hadjichristodoulou, Christos |
author_facet | Koureas, Michalis Bogogiannidou, Zacharoula Vontas, Alexandros Kyritsi, Maria A. Mouchtouri, Varvara A. Dadouli, Katerina Anagnostopoulos, Lemonia Mina, Paraskevi Matziri, Alexia Ntouska, Maria Tsigaridaki, Maria Gkiata, Vasiliki Tsilidis, Konstantinos K. Ntzani, Evangelia E. Prezerakos, Panagiotis Tsiodras, Sotirios Speletas, Matthaios Hadjichristodoulou, Christos |
author_sort | Koureas, Michalis |
collection | PubMed |
description | Background: Nation-wide SARS-CoV-2 seroprevalence surveys provide valuable insights into the course of the pandemic, including information often not captured by routine surveillance of reported cases. Methods: A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between March and December 2020. It was designed as a cross-sectional survey repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Results: Of 55,947 serum samples collected, 705 (1.26%) were found positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (9.09%) observed in December 2020. Highest seropositivity levels were observed in the “0–29” and “30–49” year age groups. Seroprevalence increased with age in the “0–29” age group. Highly populated metropolitan areas were characterized with elevated seroprevalence levels (11.92% in Attica, 12.76% in Thessaloniki) compared to the rest of the country (5.90%). The infection fatality rate (IFR) was estimated at 0.451% (95% CI: 0.382–0.549%) using aggregate data until December 2020, and the ratio of actual to reported cases was 9.59 (7.88–11.33). Conclusions: The evolution of seroprevalence estimates aligned with the course of the pandemic and varied widely by region and age group. Young and middle-aged adults appeared to be drivers of the pandemic during a severe epidemic wave under strict policy measures. |
format | Online Article Text |
id | pubmed-8871128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88711282022-02-25 SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era Koureas, Michalis Bogogiannidou, Zacharoula Vontas, Alexandros Kyritsi, Maria A. Mouchtouri, Varvara A. Dadouli, Katerina Anagnostopoulos, Lemonia Mina, Paraskevi Matziri, Alexia Ntouska, Maria Tsigaridaki, Maria Gkiata, Vasiliki Tsilidis, Konstantinos K. Ntzani, Evangelia E. Prezerakos, Panagiotis Tsiodras, Sotirios Speletas, Matthaios Hadjichristodoulou, Christos Diagnostics (Basel) Article Background: Nation-wide SARS-CoV-2 seroprevalence surveys provide valuable insights into the course of the pandemic, including information often not captured by routine surveillance of reported cases. Methods: A serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between March and December 2020. It was designed as a cross-sectional survey repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Results: Of 55,947 serum samples collected, 705 (1.26%) were found positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (9.09%) observed in December 2020. Highest seropositivity levels were observed in the “0–29” and “30–49” year age groups. Seroprevalence increased with age in the “0–29” age group. Highly populated metropolitan areas were characterized with elevated seroprevalence levels (11.92% in Attica, 12.76% in Thessaloniki) compared to the rest of the country (5.90%). The infection fatality rate (IFR) was estimated at 0.451% (95% CI: 0.382–0.549%) using aggregate data until December 2020, and the ratio of actual to reported cases was 9.59 (7.88–11.33). Conclusions: The evolution of seroprevalence estimates aligned with the course of the pandemic and varied widely by region and age group. Young and middle-aged adults appeared to be drivers of the pandemic during a severe epidemic wave under strict policy measures. MDPI 2022-01-25 /pmc/articles/PMC8871128/ /pubmed/35204386 http://dx.doi.org/10.3390/diagnostics12020295 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Koureas, Michalis Bogogiannidou, Zacharoula Vontas, Alexandros Kyritsi, Maria A. Mouchtouri, Varvara A. Dadouli, Katerina Anagnostopoulos, Lemonia Mina, Paraskevi Matziri, Alexia Ntouska, Maria Tsigaridaki, Maria Gkiata, Vasiliki Tsilidis, Konstantinos K. Ntzani, Evangelia E. Prezerakos, Panagiotis Tsiodras, Sotirios Speletas, Matthaios Hadjichristodoulou, Christos SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era |
title | SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era |
title_full | SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era |
title_fullStr | SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era |
title_full_unstemmed | SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era |
title_short | SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era |
title_sort | sars-cov-2 sero-surveillance in greece: evolution over time and epidemiological attributes during the pre-vaccination pandemic era |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871128/ https://www.ncbi.nlm.nih.gov/pubmed/35204386 http://dx.doi.org/10.3390/diagnostics12020295 |
work_keys_str_mv | AT koureasmichalis sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT bogogiannidouzacharoula sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT vontasalexandros sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT kyritsimariaa sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT mouchtourivarvaraa sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT dadoulikaterina sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT anagnostopouloslemonia sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT minaparaskevi sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT matzirialexia sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT ntouskamaria sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT tsigaridakimaria sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT gkiatavasiliki sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT tsilidiskonstantinosk sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT ntzanievangeliae sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT prezerakospanagiotis sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT tsiodrassotirios sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT speletasmatthaios sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera AT hadjichristodoulouchristos sarscov2serosurveillanceingreeceevolutionovertimeandepidemiologicalattributesduringtheprevaccinationpandemicera |